CLINICAL TRIAL TO EVALUATE THE PREVENTION OF EVENTS WITH ANGIOTENSINCONVERTING ENZYME INHIBITOR THERAPY



NIH GUIDE, Volume 23, Number 37, October 21, 1994



RFP AVAILABLE:  NHLBI-HC-94-31



P.T. 34



Keywords:

  Cardiovascular Diseases 

  Enzymes 

  Inhibitors 

  Clinical Trial 



National Heart, Lung, and Blood Institute



The National Heart, Lung, and Blood Institute (NHLBI) is soliciting

proposals for a clinical trial center to determine whether or not the

addition of an angiotensin converting enzyme (ACE) inhibitor to

standard therapy in patients with known coronary artery disease and

preserved left ventricular function will prevent cardiovascular

mortality and reduce the risk of experiencing a myocardial

infarction.  Other secondary endpoints will also be studied.  A

minimum of 14,000 patients will be enrolled.  The anticipated period

of performance is eight years beginning on or about August 1, 1995.

The Request for Proposal (RFP) NHLBI-HC-94-31 will be released on or

about October 17, 1994 with proposals due on December 5, 1994.  One

award is anticipated from this RFP.



INQUIRIES



Requests must be in writing, cite RFP NHLBI-HC-94-31, and be

addressed to:



Ms. Peggy Mills

ECA Contract Section

National Heat, Lung, and Blood Institute

Federal Building, Room 200

7550 Wisconsin Avenue

Bethesda, MD  20892



.


Return to 1994 Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.